Literature DB >> 26564072

Neurofibromatosis type 2.

D G R Evans1.   

Abstract

Type 2 neurofibromatosis (NF2) is an autosomal dominant disorder caused by mutations in the NF2 tumor suppressor gene NF2 on chromosome 22. Around 1 in 33000 people are born with an NF2 mutation although more than one-third of the 60% of de novo cases are not conceived with the mutation but this develops later in embryogenesis (mosaics). NF2 has a substantial effect on life expectancy and individuals with a constitutional truncating mutation have the worst prognosis. The vast majority of people with NF2 will develop bilateral vestibular schwannomas with many developing schwannomas on other cranial, spinal and peripheral nerves. Cranial and spinal meningiomas and intraspinal low grade indolent ependymomas are the other major tumor features. Cutaneous features can be subtle with only 70% having evidence of intracutaneous plaque-like schwannomas or subcutaneous lesions on peripheral nerves. Café-au-lait patches are more frequent than in the general population but in only around 1% will meet NIH criteria for NF1.
© 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  NF2; café-au-lait; cataract; ependymoma; hamartoma; meningioma; schwannoma

Mesh:

Year:  2015        PMID: 26564072     DOI: 10.1016/B978-0-444-62702-5.00005-6

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  11 in total

1.  Plexiform Schwannoma of the Oral Cavity: Report of Eight Cases and a Review of the Literature.

Authors:  Angela C Chi; Brad W Neville; Lisa Cheng
Journal:  Head Neck Pathol       Date:  2020-04-08

Review 2.  CNS Tumors in Neurofibromatosis.

Authors:  Jian Campian; David H Gutmann
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

3.  EANO guideline on the diagnosis and treatment of vestibular schwannoma.

Authors:  Roland Goldbrunner; Michael Weller; Jean Regis; Morten Lund-Johansen; Pantelis Stavrinou; David Reuss; D Gareth Evans; Florence Lefranc; Kita Sallabanda; Andrea Falini; Patrick Axon; Olivier Sterkers; Laura Fariselli; Wolfgang Wick; Joerg-Christian Tonn
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

4.  Neurofibromatosis type 2 initially presenting as a preauricular mass: a case report.

Authors:  Wei-Che Lan; Yu Aoh; Rui-Yun Chen; Hui-Chi Tien; Chia-Der Lin
Journal:  J Otolaryngol Head Neck Surg       Date:  2020-06-26

Review 5.  Optic nerve sheath meningiomas: prevalence, impact, and management strategies.

Authors:  Richard T Parker; Christopher A Ovens; Clare L Fraser; Chameen Samarawickrama
Journal:  Eye Brain       Date:  2018-10-24

6.  Nonsteroidal sulfamate derivatives as new therapeutic approaches for Neurofibromatosis 2 (NF2).

Authors:  Yu-Chi Shen; Caroline Arellano-Garcia; Rosa E Menjivar; Ethan M Jewett; Wolfgang Dohle; Sofiia Karchugina; Jonathan Chernoff; Barry V L Potter; Kate F Barald
Journal:  BMC Pharmacol Toxicol       Date:  2019-11-15       Impact factor: 2.483

7.  Optical coherence tomography significance in managing complex neurofibromatosis 2-related papilledema: Report of a case.

Authors:  Giacomo Maria Bacci; Flavio Giordano; Iacopo Sardi; Gareth Evans; Omar Pathmanaban; Carla Fonte; Franco Trabalzini; Sergio Nappini; Regina Mura; Roberto Caputo
Journal:  JRSM Open       Date:  2021-01-11

8.  Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas.

Authors:  D Bradley Welling; Katharine A Collier; Sarah S Burns; Janet L Oblinger; Edina Shu; Beth A Miles-Markley; Craig C Hofmeister; Mina S Makary; H Wayne Slone; Jaishri O Blakeley; S Alireza Mansouri; Brian A Neff; Robert K Jackler; Amir Mortazavi; Long-Sheng Chang
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-08-20

9.  Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2.

Authors:  Srivandana Akshintala; Nashwa Khalil; Kaleb Yohay; Alona Muzikansky; Jeffrey Allen; Anna Yaffe; Andrea M Gross; Michael J Fisher; Jaishri O Blakeley; Beverly Oberlander; Miriam Pudel; Celia Engelson; Jaime Obletz; Carole Mitchell; Brigitte C Widemann; David A Stevenson; Scott R Plotkin
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

10.  Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

Authors:  Robert Allaway; Steve P Angus; Roberta L Beauchamp; Jaishri O Blakeley; Marga Bott; Sarah S Burns; Annemarie Carlstedt; Long-Sheng Chang; Xin Chen; D Wade Clapp; Patrick A Desouza; Serkan Erdin; Cristina Fernandez-Valle; Justin Guinney; James F Gusella; Stephen J Haggarty; Gary L Johnson; Salvatore La Rosa; Helen Morrison; Alejandra M Petrilli; Scott R Plotkin; Abhishek Pratap; Vijaya Ramesh; Noah Sciaky; Anat Stemmer-Rachamimov; Tim J Stuhlmiller; Michael E Talkowski; D Bradley Welling; Charles W Yates; Jon S Zawistowski; Wen-Ning Zhao
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.